We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+9.8%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$33.5M
Cap. Flow
+$39.4M
Cap. Flow %
2.34%
Top 10 Hldgs %
67.67%
Holding
67
New
9
Increased
19
Reduced
9
Closed
16

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$47.8M
2
ASND icon
Ascendis Pharma A/S
ASND
+$44.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$34.3M
4
SNY icon
Sanofi
SNY
+$30.8M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$19.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$29.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18.1M
3
IRTC icon
iRhythm Holdings
IRTC
+$17.6M
4
UTHR icon
United Therapeutics
UTHR
+$14.7M
5
LLY icon
Eli Lilly
LLY
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
51
Adicet Bio
ACET
$75.3M
– –
-30,748
Closed -$7M
ARQT icon
52
Arcutis Biotherapeutics
ARQT
$3.48B
– –
-274,330
Closed -$5.24M
EW icon
53
Edwards Lifesciences
EW
$47.8B
– –
-147,200
Closed -$12.2M
GILD icon
54
Gilead Sciences
GILD
$162B
– –
-482,400
Closed -$29.8M
INSM icon
55
Insmed
INSM
$22.7B
– –
-220,665
Closed -$4.75M
IRTC icon
56
iRhythm Holdings
IRTC
$3.69B
– –
-140,095
Closed -$17.6M
ISRG icon
57
Intuitive Surgical
ISRG
$128B
– –
-96,300
Closed -$18.1M
IWM icon
58
PUT
iShares Russell 2000 ETF
IWM
$80.3B
– –
-200,000
Closed -$33M
LLY icon
59
Eli Lilly
LLY
$1.07T
– –
-45,500
Closed -$14.7M
MRK icon
60
CALL
Merck
MRK
$323B
– –
-300,000
Closed -$25.8M
QQQ icon
61
PUT
Invesco QQQ Trust
QQQ
$449B
– –
-150,000
Closed -$40.1M
RGNX icon
62
Regenxbio
RGNX
$622M
– –
-213,959
Closed -$5.66M
XLV icon
63
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
– –
-300,000
Closed -$36.3M
NGM
64
CALL
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-150,000
Closed -$1.96M
AKUS
65
DELISTED
Akouos Inc
AKUS
– –
-1,515,074
Closed -$10.2M
INBX
66
PUT
DELISTED
Inhibrx, Inc. Common Stock
INBX
– –
-350,000
Closed -$6.28M
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Sofinnova Investments held 67 positions worth $1.69B, down 1.9% from $1.72B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments's Q4 2022 filing shows 9 new, 19 increased, 9 reduced and 16 closed positions. Its largest new stake was Vertex Pharmaceuticals: 156,989 shares worth $45.3M. The largest sale was Gilead Sciences, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 91% a quarter earlier.

  • Sofinnova Investments's largest Q4 2022 buy was Vertex Pharmaceuticals: 156,989 shares worth $45.3M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q4 2022, an estimated $44.2M increase.
  • Sofinnova Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $14.7M.
  • Sofinnova Investments fully exited Gilead Sciences in Q4 2022, selling an estimated $29.8M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.69B portfolio in Q4 2022.
  • Sofinnova Investments opened 9 new positions and closed 16 in Q4 2022.
  • Sofinnova Investments's portfolio value fell 1.9% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q4 2022, filed 14 Feb 2023.